ENLV vs EPRX

Enlivex Ltd. vs Eupraxia Pharmaceuticals Inc. — Valuation Comparison 2026

ENLV

Pharmaceutical Preparations
Enlivex Ltd.
Quality
1.6
out of 10
Value Trap
12
SAFE
Price
$0.81
Last close
Models
6/13
Active
VS

EPRX

Pharmaceutical Preparations
Eupraxia Pharmaceuticals Inc.
Quality
1.9
out of 10
Value Trap
6
SAFE
Price
$7.09
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ENLV Fair ValueENLV Upside EPRX Fair ValueEPRX Upside
Bayesian DCF Intrinsic $0.18 -77.4% $1.82 -74.3%
EROIC Spread Intrinsic $0.39 -51.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $0.64 -21.3% $4.13 -41.8%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ENLV vs EPRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ENLV vs EPRX — Which Stock Is More Undervalued?

EPRX scores higher with a 1.9/10 quality rating vs ENLV's 1.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Enlivex Ltd. (ENLV) and Eupraxia Pharmaceuticals Inc. (EPRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ENLV currently trades at $0.81 with a QOC of 1.6/10, while EPRX trades at $7.09 with a QOC of 1.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).